文献速递中医内科中药与中成药合理使用

虎杖颗粒治疗急性痛风性关节炎的双盲随机对照试验

Efficacy and safety of Huzhang Granule, a compound Chinese herbal medicine, for acute gouty arthritis: A double-blind, randomized controlled trial.
PubMed 文献 · J Integr Med · 2024-03-16

本研究为双盲随机对照试验,纳入180例急性痛风性关节炎患者,比较虎杖颗粒与依托考昔治疗5天的疗效与安全性。结果显示两组疼痛缓解程度相似,虎杖颗粒组不良事件发生率更低(4.44% vs 13.33%),表明虎杖颗粒可作为潜在治疗选择。

要点

  • 虎杖颗粒治疗急性痛风性关节炎的镇痛效果与依托考昔相当。
  • 虎杖颗粒组不良事件发生率显著低于依托考昔组。
  • 虎杖颗粒可作为急性痛风性关节炎的潜在治疗选项。

核心结论

  • 虎杖颗粒与依托考昔在急性痛风性关节炎患者中显示出相似的镇痛效果。
  • 虎杖颗粒的安全性和有效性表明其可作为治疗急性痛风性关节炎的潜在选择。

研究设计与样本

  • 本研究为非劣效性随机对照临床试验,纳入180例符合条件的急性痛风性关节炎患者。
  • 参与者随机分为虎杖颗粒组和依托考昔组,治疗5天,采用双盲双模拟设计。

主要发现

  • 虎杖颗粒组疼痛平均减轻-51.22 mm(95%CI [-53.42, -49.03] mm),依托考昔组为-52.00 mm(95%CI [-54.06, -49.94] mm)。
  • 两组平均差异为0.78 mm(95%CI [-2.25, 3.81] mm)。
  • 所有次要疗效终点均证实非劣效性。
  • 虎杖颗粒组不良事件发生率为4.44%,依托考昔组为13.33%(P ≤ 0.05)。

关键数值与推荐

  • 主要结局为治疗第2至5天痛风关节疼痛视觉模拟评分(0-100 mm)的变化。
  • 次要结局包括关节压痛和肿胀、炎症标志物下降以及患者和研究者整体疗效评价。

临床怎么用

  • 对于急性痛风性关节炎患者,可考虑使用虎杖颗粒作为依托考昔的替代治疗。
  • 虎杖颗粒治疗5天可有效缓解疼痛,且不良事件发生率较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute gouty arthritis (AGA) is an inflammatory joint disease with a high prevalence. Typical medical interventions, including nonsteroidal anti-inflammatory drugs, colchicine and glucocorticoids, can have serious adverse reactions. Huzhang Granule (HZG), a compound Chinese herbal medicine, has been used to treat AGA for more than 30 years with satisfactory effects and no significant adverse reactions. However, the efficacy and safety of HZG in AGA patients remains unknown. OBJECTIVE: The present investigation was designed to examine the efficacy and safety profile of HZG in managing AGA patients. DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: The current study was conducted as a noninferiority, randomized controlled clinical trial on 180 eligible enrolled participants. Participants were randomly assigned into the HZG and etoricoxib groups. Treatments were administered for 5 d, during which the HZG group received HZG and placebo etoricoxib, while the etoricoxib group received etoricoxib and placebo HZG in the same ratio (1:1). MAIN OUTCOME MEASURES: The primary outcome was pain experienced by the patient in the gout-afflicted joint from days 2 to 5 of the treatment window. The pain level was measured via a visual analogue scale, ranging from 0 mm to 100 mm. The secondary outcomes comprised joint tenderness and swelling, reduction of inflammatory biomarkers, and the patient's and investigator's global evaluations of therapeutic response. RESULTS: The mean reduction in pain was -51.22 mm (95% confidence interval [CI], [-53.42, -49.03] mm) for the HZG and -52.00 mm (95% CI, [-54.06, -49.94] mm) for the etoricoxib groups. The mean difference between the two groups was 0.78 mm (95% CI, [-2.25, 3.81] mm). All additional efficacy endpoints, covering decreased inflammation and pain relief, yielded compelling proof of noninferiority. Patients in the HZG group exhibited a comparatively lower rate of adverse events compared to those in the etoricoxib group (4.44% vs 13.33%; P ≤ 0.05). CONCLUSION: HZG and etoricoxib groups demonstrated similar levels of analgesic effectiveness. The safety and efficacy of HZG indicates that it can be used as a potential therapeutic option for treating AGA. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2000036970). Please cite this article as: Wang H, Chen ST, Ding XJ, Kuai L, Hua L, Li X, Wang YF, Zhang M, Li B, Wang RP, Zhou M. Efficacy and safety of Huzhang Granule, a compound Chinese herbal medicine, for acute gouty arthritis: A double-blind, randomized controlled trial. J Integr Med. 2024; 22(3): 270-278.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Wang H, Chen ST, Ding XJ, et al. Efficacy and safety of Huzhang Granule, a compound Chinese herbal medicine, for acute gouty arthritis: A double-blind, randomized controlled trial. J Integr Med. 2024. PMID: 38553375. doi:10.1016/j.joim.2024.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。